Clearside Biomedical

Clearside Biomedical Enterprise Value

Delisted

The Enterprise Value (EV) of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -16.50 M USD. In the previous year, Enterprise Value (EV) was -25.40 M USD — a change of -35.04% (higher).

Enterprise Value

-16.50 MUSD

YoY

-35.04%

Last updated:

Enterprise Value (EV) of Clearside Biomedical is 2024 -16.50 M USD. Enterprise Value (EV) of Clearside Biomedical was 2023 -25.40 M USD. It decreases by -35.04% higher compared to the previous year.

The Clearside Biomedical Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2017
-26.11 M USD
Jan 1, 2018
-27.38 M USD
Jan 1, 2019
-13.93 M USD
Jan 1, 2020
-12.78 M USD
Jan 1, 2021
-26.92 M USD
Jan 1, 2022
-44.74 M USD
Jan 1, 2023
-25.40 M USD
Jan 1, 2024
-16.50 M USD
The Clearside Biomedical Enterprise Value history
YEAREnterprise ValueYoY
-16.50 MUSD-35.04%
-25.40 MUSD-43.23%
-44.74 MUSD+66.20%
-26.92 MUSD+110.64%
-12.78 MUSD-8.26%
-13.93 MUSD-49.12%
-27.38 MUSD+4.86%
-26.11 MUSD-64.00%
-72.52 MUSD+572.73%
-10.78 MUSD+126.95%
-4.75 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Enterprise Value (EV) of Clearside Biomedical is -16.50 M USD in 2024.

Enterprise Value (EV) of Clearside Biomedical changed from -25.40 M USD to -16.50 M USD, representing a -35.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Clearside Biomedical

All Key Metrics — Clearside Biomedical